Expanding the ability to target cancer-related proteins for new treatments
Chemical Proteomic Platforms for Radically Expanding Cancer Druggability
This study is exploring new ways to create treatments for cancer by finding special tools that can target proteins that are hard to treat, with the hope that these new therapies will help patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10903992 on NIH RePORTER |
What this research studies
This research focuses on identifying and developing chemical probes for proteins associated with cancer that are currently considered undruggable. By utilizing advanced activity-based protein profiling (ABPP) technology, the team aims to create new therapies by mapping the interactions of small molecules with thousands of proteins in their natural biological environments. The goal is to translate the insights gained from modern human genetics into effective treatments for cancer and immuno-oncology. Patients may benefit from new targeted therapies that arise from this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers driven by specific genetic mutations that have not yet been effectively targeted by existing therapies.
Not a fit: Patients with cancers that are already well-targeted by existing treatments may not receive additional benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new cancer treatments that target previously undruggable proteins.
How similar studies have performed: While the approach of expanding druggability through innovative profiling technologies is relatively novel, similar strategies have shown promise in other areas of cancer research.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Cravatt, Benjamin F — Scripps Research Institute, the
- Study coordinator: Cravatt, Benjamin F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.